This presentation provides a comprehensive overview of the current pharmaceutical industry. It begins with a look at some of the changes facing the industry and then moves into a discussion on digital technology and its impact on pharmaceutical companies. From there, the deck explores two digital trends, mobile and eDetailing. The presentation wraps up with some examples of pharmaceutical companies their digital presence.
This presentation covers the Introduction to Healthcare & different Products, Role of Pharmaceutical in Healthcare, Drug Details, What a drug is made of ?, Classification of drugs, Product Life Cycle of a Drug, Drug Development Phases, Regulatory Framework & various Regulatory Bodies
Global pharmaceutical companies are modeled with a supply chain, which ensures that the right drug reaches the right people at the right time and in the right condition. The supply chain also ensures 100% product availability at optimum cost by carrying huge inventory, which maintains 100% fill rate. Manufacturers are trying to cut down development time to save costs. For example, a drug manufacturer who can trim development time by 19% can save up to USD 100 million. But if a drug is getting delayed to reach the market, the time delay costs the company around USD 1 million a day. So, pharmaceutical companies today are designing the supply chain to be as responsive as possible to reduce entry time to the market thereby increasing profit margins.
A presentation I did for my Leadership and Special Topics in Pharmaceutical Marketing and Management class on social media. I completed this project with Tae Lee.
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...IMARC Group
According to the latest report by IMARC Group,the global oncology biosimilars market exhibited strong growth during 2015-2020.
Oncology biosimilars are cost-effective counterparts of the already licensed reference biologics.
This presentation covers the Introduction to Healthcare & different Products, Role of Pharmaceutical in Healthcare, Drug Details, What a drug is made of ?, Classification of drugs, Product Life Cycle of a Drug, Drug Development Phases, Regulatory Framework & various Regulatory Bodies
Global pharmaceutical companies are modeled with a supply chain, which ensures that the right drug reaches the right people at the right time and in the right condition. The supply chain also ensures 100% product availability at optimum cost by carrying huge inventory, which maintains 100% fill rate. Manufacturers are trying to cut down development time to save costs. For example, a drug manufacturer who can trim development time by 19% can save up to USD 100 million. But if a drug is getting delayed to reach the market, the time delay costs the company around USD 1 million a day. So, pharmaceutical companies today are designing the supply chain to be as responsive as possible to reduce entry time to the market thereby increasing profit margins.
A presentation I did for my Leadership and Special Topics in Pharmaceutical Marketing and Management class on social media. I completed this project with Tae Lee.
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...IMARC Group
According to the latest report by IMARC Group,the global oncology biosimilars market exhibited strong growth during 2015-2020.
Oncology biosimilars are cost-effective counterparts of the already licensed reference biologics.
This document presents an analysis of the current state of the biosimilar market as well as its perspectives of evolution, with a particular focus on the French market
The U.S. Biopharmaceutical Industry (2014): Perspectives on Future Growth and...PhRMA
The capability to innovate is fast becoming the most important determinant of economic growth and a nation’s ability to compete and prosper in the 21st century global knowledge-based economy.
The innovative biopharmaceutical industry stands out among high-value knowledge-based industries, including aerospace, automotive, and semiconductors, as a driver for future U.S. economic growth. Aging populations throughout the world and rising purchasing power for medical advances among emerging economies are expected to drive increased demand for prescription medicines in the coming years, providing opportunities to increase production and exports.
Global regenerative medicines market (technology, application and geography) ...Allied Market Research
Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process.
7th Pharmacovigilance 2014 “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management" 21st November 2014, Kohinoor Continental Hotel, Mumbai, India Greetings from Virtue Insight, I am happy to invite you and your colleagues to be a sponsor / delegate for our upcoming conference. The “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management” at 7th Pharmacovigilance 2014 on 21st November 2014, Kohinoor Continental Hotel, Mumbai, India.Contact:-Tel: +91 9677590192 Email: dinesh@virtueinsight.co.in
This whitepaper provides an overview of Chinese pharmaceutical market access. This includes an overview of the Chinese pharmaceutical market, government regulatory bodies,distribution channels, demographics, pricing and insurance. It also includes an overview of current regulations and product registration procedures.
This paper is meant for anyone within the pharmaceutical industry who is looking to learn more about how to access the pharmaceutical market in China.
For more information, contact us for a free 15 minute consultation at http://www.pacificbridgemedical.com/contact-us/.
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “5th Pharmacovigilance Congregation 2013” The conference will be held on 20th November 2013, Kohinoor Continental Hotel, Mumbai, India.
French generics market attractiveness 2017 - 2022 excerptJean-Michel Peny
This excerpt of a report published in 2017 describes and explains the dynamics of the French generics and biosimilars markets in France, and evaluate their attractiveness by 2022
This document presents an analysis of the current state of the biosimilar market as well as its perspectives of evolution, with a particular focus on the French market
The U.S. Biopharmaceutical Industry (2014): Perspectives on Future Growth and...PhRMA
The capability to innovate is fast becoming the most important determinant of economic growth and a nation’s ability to compete and prosper in the 21st century global knowledge-based economy.
The innovative biopharmaceutical industry stands out among high-value knowledge-based industries, including aerospace, automotive, and semiconductors, as a driver for future U.S. economic growth. Aging populations throughout the world and rising purchasing power for medical advances among emerging economies are expected to drive increased demand for prescription medicines in the coming years, providing opportunities to increase production and exports.
Global regenerative medicines market (technology, application and geography) ...Allied Market Research
Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process.
7th Pharmacovigilance 2014 “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management" 21st November 2014, Kohinoor Continental Hotel, Mumbai, India Greetings from Virtue Insight, I am happy to invite you and your colleagues to be a sponsor / delegate for our upcoming conference. The “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management” at 7th Pharmacovigilance 2014 on 21st November 2014, Kohinoor Continental Hotel, Mumbai, India.Contact:-Tel: +91 9677590192 Email: dinesh@virtueinsight.co.in
This whitepaper provides an overview of Chinese pharmaceutical market access. This includes an overview of the Chinese pharmaceutical market, government regulatory bodies,distribution channels, demographics, pricing and insurance. It also includes an overview of current regulations and product registration procedures.
This paper is meant for anyone within the pharmaceutical industry who is looking to learn more about how to access the pharmaceutical market in China.
For more information, contact us for a free 15 minute consultation at http://www.pacificbridgemedical.com/contact-us/.
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “5th Pharmacovigilance Congregation 2013” The conference will be held on 20th November 2013, Kohinoor Continental Hotel, Mumbai, India.
French generics market attractiveness 2017 - 2022 excerptJean-Michel Peny
This excerpt of a report published in 2017 describes and explains the dynamics of the French generics and biosimilars markets in France, and evaluate their attractiveness by 2022
IT can do a revolution in many industries like health. Ksoft Technologies, cherppulassery does this through websites, mobile apps and computer software.
You can have a quick look into it's website and portfolio for more opportunities and needs - www.ksofttechnologies.com
Let's make it work !
Solutions targeted to patients, doctors, pharmaceuticals, hospitals and healthcare authorities. All of them strategically packaged to improve service delivery and enhance customer experience.
This presentation provides a comprehensive overview of the current insurance industry. The focus is to further explore life, health and auto insurance, as well as some new trends, ideas and disruptions facing this sector. From there, we move into a discussion on consumer tools. This section breaks down customer insurance behaviors, and the changes coming up in 2014. To end we take a look into how various companies are leveraging technologies to advance the industry.
2016 IBM Interconnect - medical devices transformationElizabeth Koumpan
Emerging technologies such as Internet of Things, 3D Printing are driving the creation of new business models and forcing the Industry for transformation. The product centric model where the Industry main objective was to develop the device, is moving to software and services model, with the focus on Big Data & Analytics, Integration and Cloud.
The maturation of technologies such as social, mobile, analytics, cloud, 3D printing, bio- and nanotechnology are rapidly shifting the competitive landscape. These emerging technologies create an environment that is connected and open, simple and intelligent, fast and scalable. Organizations must embrace disruptive technologies to drive innovation
Drug Information Association (DIA) Magazine (select article from Page 11 only) authored by John Reites on 14Dec2015.
Today’s consumers expect seamless, value-driven experiences when they engage with a brand. From buying products online, to getting text alerts about doctors’ appointments, to completing transactions via mobile apps, they assume every interaction will be painless and pleasant – and participating in a clinical trial is no exception.
People join these research studies to improve their health and contribute data for the care of others – and in exchange, they expect their research experience to be positive, accommodating of their time, and intuitive. If it’s not, the cost-benefit scenario can shift, and they may decide it’s not worth the effort.
A summary of macro level trends and issues that are driving the need for enhanced digital marketing and service delivery in the Pharma/Healthcare industry. Included are case studies presented at the recent ePharm Summit in NYC.
In this digital era, the healthcare sector is going through a remarkable revolution enabled by sophisticated technologies. Amongst these advancements, web development has been particularly instrumental in enhancing the industry's capabilities.
Opening Keynote: The Convergence of mHealth: A Consumer and Clinical Perspective
Description: In the opening keynote attendees will hear an overview from a current HIMSS mHealth Community Member which sets the stage for discussion. The keynote will highlight facts and figures which support the thesis of increased utilization of mobile and wireless technologies by healthcare providers. The keynote will also set the stage with current issues impacting the continued adoption.
Speaker(s): Ahmed Albaiti
Objectives: Assess the current landscape of mHealth. Illustrate the roles of consumers and patients. Define the current issues.
In this presentation, I tried to succinctly discuss the future technology trends and explain how they can impact the healthcare industry. Also Business Transformation, as a key to tackle, has been discussed.
The Ultimate Guide to Healthcare App Development.pdfLucy Zeniffer
Planning to build a healthcare application? Here is your expert’s guide on steps to build a healthcare app, including types, features, and benefits of healthcare applications.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
4. statistics
industry overview
86% of physicians
in the US use the
web to gather
health, medical or
prescription drug
info1
53% of consumers
polled say
information found
online led them to
ask a doctor new
questions3
98% of physicians
agree that their
use of the internet
for medicine will
increase over the
next 3 years2
1-3. Roman, Shawn, Donna Tuths, and Jason Wolenik. "Digital: The Connecter in Life Sciences." Accenture. N.p., n.d. Web. 2011.
5. typesofpharmaceuticals
industry overview
brand name
marketed under a specific trade name by a pharmaceutical
manufacturer and are still under patent protection
generic
made with the same active ingredients in the same dosage form
as a brand name drug, but are sold to customers under their
chemical name for 30-80% less
7. fundamentalchanges
industry overview
• increasing demand for health care services and prescription
medication to treat diseases
• physicians are refusing to meet with sales reps in person
• new technology allowing doctors and patients to access
pharmaceutical information online
• increasing threat of patent cliffs, litigation and legislation4
4. Roman, Shawn, Donna Tuths, and Jason Wolenik. "Digital: The Connecter in Life Sciences." Accenture. N.p., n.d. Web. 2011.
8. sellingprocess
industry overview
sales calls - reps from top companies target high volume
prescribing doctors over the phone
office visits - reps pass out free samples to physicians, this
method is on the decline, statistics suggest out of 100 sales reps
only 20 actually meet with a doctor5
online - reps engage online with doctors and patients through
eDetailing
5."Pharmaceutical Sales Force Effectiveness Metrics." Eularis. N.p., n.d. Web. <http://www.slideshare.net/EULARIS/pharmaceutical-sales-force-effectiveness-metrics>.
9. globaldigitalstrategy
industry overview
5 areas of focus
1. choosing the right digital operating model
2. integrating all channels
3. using analytics as a differentiator
4. finding new approaches for developing content
5. focusing on flexible and responsive technology
architecture6
6. Roman, Shawn, Donna Tuths, and Jason Wolenik. "Digital: The Connecter in Life Sciences." Accenture. N.p., n.d. Web. 2011.
10. step#1
industry overview
creating the right digital operating model
• agile and flexible model that allows for customization at the
local level
• move towards centralization for digital capabilities such as,
website development, mobile apps and digital asset
management in order to create a cohesive customer
experience
• focus on hiring the talent needed to meet the digital needs
within the organization7
7. Roman, Shawn, Donna Tuths, and Jason Wolenik. "Digital: The Connecter in Life Sciences." Accenture. N.p., n.d. Web. 2011.
11. step#2
industry overview
seamlessly integrating all channels
• consistent interactions across all channels will drive
meaningful customer interactions
• need to gather information about customer interactions on
all channels to create a holistic and realistic picture of their
customers8
8. Roman, Shawn, Donna Tuths, and Jason Wolenik. "Digital: The Connecter in Life Sciences." Accenture. N.p., n.d. Web. 2011.
12. step#3
industry overview
using analytics as a differentiator
• use data collected from all channels to assess the impact of
digital campaigns and make real time adjustments based on
customer engagement
• use advanced marketing analytics to enable competitive
differentiation, companies will be able to spot trends faster
and act on them more quickly9
9. Roman, Shawn, Donna Tuths, and Jason Wolenik. "Digital: The Connecter in Life Sciences." Accenture. N.p., n.d. Web. 2011.
13. step#4
industry overview
embracing new approaches for developing content
• automating processes will allow the same number of
employees to handle increased demand
• creating content that can be used across multiple channels
without modification will be crucial (optimized sites, videos
etc.)10
10. Roman, Shawn, Donna Tuths, and Jason Wolenik. "Digital: The Connecter in Life Sciences." Accenture. N.p., n.d. Web. 2011.
14. step#5
industry overview
using a flexible and responsive technology architecture
• the right architecture will extend overall customer reach and
increase promotional capacity across all channels
• integrated channels allows for sharing customer information
across channels and leads to a more cohesive customer
experience11
11. Roman, Shawn, Donna Tuths, and Jason Wolenik. "Digital: The Connecter in Life Sciences." Accenture. N.p., n.d. Web. 2011.
16. salesreps
trends
• companies are arming their
sales forces with tablets to
enable sales, train staff and
conduct administrative
• result is a tailored approach
to individual doctors with a
clear marketing message
relevant to doctor's
individual practices and
patients
17. doctors
trends
• doctors are sharing patient
information, recording diagnoses
and billing codes across mobile
devices to eliminate the need for
patient cards
• the mobile/iPad app costs $99 a
month and provides a template
for doctors to follow while
dictating information
• the audio files, transcripts and
relevant images (ie. photo of a
patient’s wristband) are encrypted
and sent to a cloud based HIPAA
compliant database12
12. Peterson, Stacey. "InformationWeek: The Business Value of Technology."InformationWeek. N.p., 05 July 2012. Web.
18. patients
trends
• patients are information seekers
when it comes to their health, many
of them are actively searching for
ways to independently educate
themselves
• they are posting health statuses on
sites like PatientsLikeMe13
• they are engaging with solutions like
Emmi, which give them access to
physician recommended info via
their mobile devices
• Emmi also allows patients to receive
information from physicians after
office visits regarding preventative
treatment options and medical
condition assistance14
13."Patientslikeme." Patientslikeme. N.p., n.d. Web. <http://www.patientslikeme.com/>.
14. Peterson, Stacey. "InformationWeek: The Business Value of Technology."InformationWeek. N.p., 05 July 2012. Web.
19. patients
trends
• VaxNation is a mobile app that
allows patients to track
vaccinations over the course of
their lifetime
• the system allows patients to
enter information such as date
of birth and prior vaccines with
corresponding dates
• the app then provides age
appropriate recommendations
based on the CDC’s prevention
guidelines as well as
immunization reminders15
15. Peterson, Stacey. "InformationWeek: The Business Value of Technology."InformationWeek. N.p., 05 July 2012. Web.
21. pharmaceuticaldetailing
trends
detailing is a one-on-one marketing technique used by
pharmaceutical companies to educate physicians about a
vendor’s products in hope that the physician will prescribe the
company’s products more often. This traditional practice has
evolved into edetailing, which utilizes technology to reach
doctors16
16. Rouse, Margaret. "Pharmaceutical Detailing." SearchHealthIT. N.p., Feb. 2011. Web.
22. IQmercury2
trends
• IQmercury2 is edetailing made
simple
• features include presentation
capabilities, such as the ability to
customize slides, track sentiments
with + or - response tags
• a remote control system, that gives
HCP’s the chance to control the
presentation via an iPhone remote
• a content management tool, that
lets users integrate CRM solutions
and review analytic data per each
presentation17
17."Unique Features Build Successful Presentations." IQmercury Features Comments. N.p., n.d. Web.
24. merck
digital presence
• merck invests 17 M in
Physicians Interactive
• PI is the leading provider of
mobile and web based clinical
resources and solutions for
healthcare professionals
• the funds will be used to fund
the growth of 4 key products
and initiatives18
• one key product is the
skyscape app, a mobile
content publisher19
18."PI Press Release." Physicians Interactive RSS. N.p., 05 Jan. 2012. Web.
19. Arnold, Matthew. "Merck Adds to Its Digital Portfolio." MMM. N.p., 01 Feb. 2012. Web.
25. pfizer
digital presence
• pfizer targets boomers
through GetOld microsite
• the site is a place where
consumers can share
and get information
about the changes that
occur during the aging
process
• a survey gives boomers
the opportunity to see
how their feelings stack
up with others their age20
20. Armstrong, Linda. "Pfizer Gets Digital Marketing to Boomers Right." No Green Bananas. N.p., n.d. Web.
26. astrazeneca
digital presence
• astrazeneca invests in a
comprehensive, interactive mobile
application solution for use by its
sales force developed by
accenture
• accenture developed a
responsive application to meet
the needs of pharma sales reps
out in the field
• the app has the ability to capture
and store metrics even in offline
mode21
21. "Helping AstraZeneca Achieve High Performance Through Digital Application Delivery." Accenture. N.p., n.d. Web.
27. novartis
digital presence
• novartis invests $200 M in integrated
ad campaign to promote heartburn
drug
• the campaign includes several digital
elements, such as online ads that
drive consumers to the
prevacid24.com site
• on the site users are prompted to join
the prevacid 24HR action program
• once users join they receive
customized email newsletters,
coupons and other money saving
offers as well as members only tools
and info22
22. Hurn, Mary E. "Novartis $200 Million Integrated Campaign Promotes Heartburn Drug."Direct Marketing News. N.p., 12 Nov. 2009. Web.
28. summary
pharmaceutical companies need to recognize the fundamental
shift away from promoting individual products. Instead the focus
is on making adjustments, both internally and externally that will
revolutionize the ways companies attract and engage with
customers to create lasting and profitable relationships.
29. opportunitiesforthefuture
online
• manufacturer sponsored support communities for patients
with similar diseases
• sites that allow online ordering and delivery of
prescriptions
• manufacturer sponsored sites to access reliable health
care information
mobile
• apps that remind patients to take medicine, schedule
followup doctor’s visits
• apps for patients to use as tools to monitor their health
(pollen monitor app or heart rate monitor app)
tablet
• customized interactive platforms with a focus on doctor
engagement for sales reps to utilize during office visits
30. propane studio | 1160 battery street, suite 350 san francisco, ca 94111 | 415.550.8692 | www.propanestudio.com
propanestudioisafull-service
digitalagencyfocusedon
developingexperiencesand
solutionsthatfuelthewaypeople
connectwithbrandsandeachother.